arrow
A

Andrea Kühnl

King's College Hospital
H指数:21
被引数:2,023

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response-adapted chimeric antigen receptor T cell (CAR-T)–sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol

高风险大B细胞淋巴瘤(LBCL)中反应适应性嵌合抗原受体T细胞(CAR-T)节约巩固放疗:前瞻性RESTART方案的成果

2026-07-030
PRE
Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma

早期PET反应预测大B细胞淋巴瘤患者接受2线axi-cel治疗后复发的风险

2026-03-310
OAAI
Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK

英国大型B细胞淋巴瘤患者接受二线阿西替尼西洛鲁塞注射液治疗的结局

2026-02-190
OAAI
Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition

CAR T细胞治疗原发性或继发性中枢神经系统淋巴瘤患者的疗效和安全性: 代表EBMT和GoCART联盟的研究

2025-05-210
OA
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

CAR T细胞制备失败的风险因素及大B细胞淋巴瘤患者结局:英国国家CAR T小组报告

2025-03-042
OA
Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Glofitamab和Epcoritamab在真实世界中的疗效、耐受性及实际意义:一项英国多中心回顾性分析

BLOOD
IF23.1
2024-11-051
PRE
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment

大b细胞淋巴瘤患者在三线或更晚线治疗car-t进展后CAR预后指数的开发和验证

2024-10-290
OAAI
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
2024-06-133
OAAI
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
2024-05-212
OAAI
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes
2024-04-040
OAAI
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
2022-05-0921
OAAI
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma
2022-01-1145
OAAI